Cargando…

ESR/ERS white paper on lung cancer screening

ABSTRACT: Lung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. Annual low-dose computed tomography has shown a survival benefit in screening individuals at high risk for lung cancer. Based on the available evidence, the European Society of Radiology and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kauczor, Hans-Ulrich, Bonomo, Lorenzo, Gaga, Mina, Nackaerts, Kristiaan, Peled, Nir, Prokop, Mathias, Remy-Jardin, Martine, von Stackelberg, Oyunbileg, Sculier, Jean-Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529446/
https://www.ncbi.nlm.nih.gov/pubmed/25929939
http://dx.doi.org/10.1007/s00330-015-3697-0
_version_ 1782384794607288320
author Kauczor, Hans-Ulrich
Bonomo, Lorenzo
Gaga, Mina
Nackaerts, Kristiaan
Peled, Nir
Prokop, Mathias
Remy-Jardin, Martine
von Stackelberg, Oyunbileg
Sculier, Jean-Paul
author_facet Kauczor, Hans-Ulrich
Bonomo, Lorenzo
Gaga, Mina
Nackaerts, Kristiaan
Peled, Nir
Prokop, Mathias
Remy-Jardin, Martine
von Stackelberg, Oyunbileg
Sculier, Jean-Paul
author_sort Kauczor, Hans-Ulrich
collection PubMed
description ABSTRACT: Lung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. Annual low-dose computed tomography has shown a survival benefit in screening individuals at high risk for lung cancer. Based on the available evidence, the European Society of Radiology and the European Respiratory Society recommend lung cancer screening in comprehensive, quality-assured, longitudinal programmes within a clinical trial or in routine clinical practice at certified multidisciplinary medical centres. Minimum requirements include: standardised operating procedures for low-dose image acquisition, computer-assisted nodule evaluation, and positive screening results and their management; inclusion/exclusion criteria; expectation management; and smoking cessation programmes. Further refinements are recommended to increase quality, outcome and cost-effectiveness of lung cancer screening: inclusion of risk models, reduction of effective radiation dose, computer-assisted volumetric measurements and assessment of comorbidities (chronic obstructive pulmonary disease and vascular calcification). All these requirements should be adjusted to the regional infrastructure and healthcare system, in order to exactly define eligibility using a risk model, nodule management and a quality assurance plan. The establishment of a central registry, including a biobank and an image bank, and preferably on a European level, is strongly encouraged. KEY POINTS: • Lung cancer screening using low dose computed tomography reduces mortality. • Leading US medical societies recommend large scale screening for high-risk individuals. • There are no lung cancer screening recommendations or reimbursed screening programmes in Europe as of yet. • The European Society of Radiology and the European Respiratory Society recommend lung cancer screening within a clinical trial or in routine clinical practice at certified multidisciplinary medical centres. • High risk, eligible individuals should be enrolled in comprehensive, quality-controlled longitudinal programmes.
format Online
Article
Text
id pubmed-4529446
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-45294462015-08-11 ESR/ERS white paper on lung cancer screening Kauczor, Hans-Ulrich Bonomo, Lorenzo Gaga, Mina Nackaerts, Kristiaan Peled, Nir Prokop, Mathias Remy-Jardin, Martine von Stackelberg, Oyunbileg Sculier, Jean-Paul Eur Radiol Special Report ABSTRACT: Lung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. Annual low-dose computed tomography has shown a survival benefit in screening individuals at high risk for lung cancer. Based on the available evidence, the European Society of Radiology and the European Respiratory Society recommend lung cancer screening in comprehensive, quality-assured, longitudinal programmes within a clinical trial or in routine clinical practice at certified multidisciplinary medical centres. Minimum requirements include: standardised operating procedures for low-dose image acquisition, computer-assisted nodule evaluation, and positive screening results and their management; inclusion/exclusion criteria; expectation management; and smoking cessation programmes. Further refinements are recommended to increase quality, outcome and cost-effectiveness of lung cancer screening: inclusion of risk models, reduction of effective radiation dose, computer-assisted volumetric measurements and assessment of comorbidities (chronic obstructive pulmonary disease and vascular calcification). All these requirements should be adjusted to the regional infrastructure and healthcare system, in order to exactly define eligibility using a risk model, nodule management and a quality assurance plan. The establishment of a central registry, including a biobank and an image bank, and preferably on a European level, is strongly encouraged. KEY POINTS: • Lung cancer screening using low dose computed tomography reduces mortality. • Leading US medical societies recommend large scale screening for high-risk individuals. • There are no lung cancer screening recommendations or reimbursed screening programmes in Europe as of yet. • The European Society of Radiology and the European Respiratory Society recommend lung cancer screening within a clinical trial or in routine clinical practice at certified multidisciplinary medical centres. • High risk, eligible individuals should be enrolled in comprehensive, quality-controlled longitudinal programmes. Springer Berlin Heidelberg 2015-05-01 2015 /pmc/articles/PMC4529446/ /pubmed/25929939 http://dx.doi.org/10.1007/s00330-015-3697-0 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Special Report
Kauczor, Hans-Ulrich
Bonomo, Lorenzo
Gaga, Mina
Nackaerts, Kristiaan
Peled, Nir
Prokop, Mathias
Remy-Jardin, Martine
von Stackelberg, Oyunbileg
Sculier, Jean-Paul
ESR/ERS white paper on lung cancer screening
title ESR/ERS white paper on lung cancer screening
title_full ESR/ERS white paper on lung cancer screening
title_fullStr ESR/ERS white paper on lung cancer screening
title_full_unstemmed ESR/ERS white paper on lung cancer screening
title_short ESR/ERS white paper on lung cancer screening
title_sort esr/ers white paper on lung cancer screening
topic Special Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529446/
https://www.ncbi.nlm.nih.gov/pubmed/25929939
http://dx.doi.org/10.1007/s00330-015-3697-0
work_keys_str_mv AT kauczorhansulrich esrerswhitepaperonlungcancerscreening
AT bonomolorenzo esrerswhitepaperonlungcancerscreening
AT gagamina esrerswhitepaperonlungcancerscreening
AT nackaertskristiaan esrerswhitepaperonlungcancerscreening
AT pelednir esrerswhitepaperonlungcancerscreening
AT prokopmathias esrerswhitepaperonlungcancerscreening
AT remyjardinmartine esrerswhitepaperonlungcancerscreening
AT vonstackelbergoyunbileg esrerswhitepaperonlungcancerscreening
AT sculierjeanpaul esrerswhitepaperonlungcancerscreening
AT esrerswhitepaperonlungcancerscreening